Molecular Phenotypic Susceptibility Testing with PCR Pathogen Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional antimicrobial susceptibility testing methods are slow, taking multiple days to complete, which hinders timely clinical decision-making in treating infections.
Innovation Solution
A method for identifying antimicrobial susceptibility of microorganisms in a biological specimen using genetic analysis and polymerase chain reaction (PCR) assays to determine the effectiveness of antimicrobial agents against identified pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional antimicrobial susceptibility testing methods are used, then accurate determination of pathogen susceptibility is achieved, but the testing process takes multiple days to complete
Solution Approach 1:
The patent replaces traditional mechanical/cultural methods (visual inspection of bacterial growth on agar plates) with molecular biological methods (PCR amplification and detection of pathogen DNA). This substitution enables rapid detection of antimicrobial susceptibility by directly analyzing genetic markers associated with drug resistance, eliminating the need for multi-day cultural growth processes while maintaining diagnostic accuracy
Solution Approach 2:
The patent performs preliminary genetic analysis to identify the presence of specific pathogen DNA sequences and their antimicrobial resistance genes before final susceptibility determination. By pre-identifying target pathogens and their resistance mechanisms through PCR amplification, the system prepares results in advance, significantly reducing the overall testing time from multiple days to hours while ensuring accurate susceptibility profiling
2Loss of time
If faster antimicrobial susceptibility testing methods are developed, then testing time is reduced, but the complexity of the testing system increases
Solution Approach 1:
The patent divides the complex testing process into distinct modular segments: (1) DNA extraction from clinical samples, (2) PCR amplification of specific pathogen genes and resistance markers, (3) Detection and analysis of amplification products, and (4) Interpretation of susceptibility results. Each segment can be performed independently with standardized protocols, reducing overall system complexity while achieving rapid results within 2-4 hours
Solution Approach 2:
The patent introduces PCR amplification as an intermediary step between sample collection and susceptibility determination. This molecular mediator enables indirect detection of antimicrobial susceptibility by amplifying and detecting specific genetic sequences associated with drug resistance, rather than directly observing bacterial growth responses. This intermediary approach simplifies the testing system while dramatically reducing testing time from days to hours
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for rapid determination of antimicrobial susceptibility, enabling prompt administration of effective treatment, thereby improving patient outcomes.
Implementation Method 1
performing a polymerase chain reaction (PCR) assay on the second sample after exposure of the second sample to the panel of the antimicrobial agents, wherein the PCR assay includes oligonucleotides that amplify a nucleic acid sequence for one or more of the identified pathogens
Data Source
AI summary
A method for identifying a pathogen includes obtaining a biological specimen. The method may include dividing the specimen into at least a first sample and a second sample. The method may include identifying at least one pathogen in the first sample via genetic analysis. The method may include exposing the second sample to a panel of antimicrobial agents at known concentrations based on the at least one pathogen. The method may include performing a polymerase chain reaction (PCR) assay on the second sample after exposure of the second sample to the panel of the antimicrobial agents, wherein the PCR assay includes oligonucleotides that amplify a nucleic acid sequence for one or more of the identified pathogens. The method may include analyzing a result of the PCR assay.